Verzenio is a prescription medication classified as a targeted therapy to treat advanced or metastatic breast cancer that is hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative. It may be used in combination with certain hormone therapies, or alone (as monotherapy). Verzenio is manufactured by Eli Lilly and Company.
What is the ingredient in Verzenio?
The active ingredient in Verzenio is abemaciclib, a kinase inhibitor that targets cyclin dependent kinase (CDK) 4 and 6.1
How does Verzenio work?
Breast cancer cells that are hormone receptor positive are stimulated by the presence of hormones like estrogen, which can increase the activity of CDK4 and 6, which are proteins involved in a cell’s growth and division. Overactivity of CDK4 and CDK6 can cause breast cancer cells to grow uncontrollably.
Verzenio targets and blocks the proteins CDK4 and CDK6. By blocking these two proteins, Verzenio can help slow the growth and division of breast cancer cells, but it may also interfere with the normal growth and division of healthy cells.1,2
What are some of the possible side effects of Verzenio?
Diarrhea, which can lead to dehydration or infection
Lowered white blood cell counts (neutropenia), which may lead to serious infections and cause symptoms such as fever and/or chills – any signs of infection should be reported immediately to a doctor
Liver problems, which can cause symptoms such as fatigue, abdominal pain on the right side, more bleeding or bruising than normal, and/or a loss of appetite – any of these symptoms should be reported immediately to a doctor
Blood clots, which may cause pain or swelling in the arms or legs, shortness of breath, chest pain, fast breathing, or a fast heart rate – any of these symptoms should be reported immediately to a doctor1,3
Lowered white blood cells, red blood cells (anemia), or platelet counts1,3
Things to know about Verzenio
Because Verzenio can lower white blood cell levels, it should not be used in patients who already have lowered white blood cell counts. Levels of white blood cells should be checked prior to starting treatment with Verzenio and throughout treatment.1
Before starting treatment with Verzenio, patients should talk to their doctor about all their medications (prescription and over-the-counter), herbal supplements, and vitamins they are taking. Some medications or supplements may interfere with each other and may cause side effects.1,3
Before starting treatment with Versenio, patients should also discuss with their doctor if they are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. Verzenio can cause harm to an unborn fetus and should not be used in pregnant women. Women who can become pregnant are advised to use effective contraception while taking Verzenio and for at least three weeks after stopping treatment with Verzenio.1,3
It is not known if Verzenio passes through breastmilk. Women should not breastfeed while taking Verzenio and for at least 3 weeks after treatment with Verzenio is finished.1,3
People taking Verzenio should avoid eating grapefruit, drinking grapefruit juice, or consuming grapefruit containing products, as grapefruit products may increase the levels of Verzenio in the body, which can increase the potential for side effects.1,3
Blood tests to monitor liver function should be performed during treatment with Verzenio.1
Verzenio comes in tablets in several different strengths: 50 mg, 100 mg, 150 mg, and 200 mg. The recommended starting dose in combination with a hormone therapy is 150 mg twice daily. For monotherapy (used alone), the recommended starting dose is 200 mg twice daily. The tablets can be taken with or without food.1
The dosage of Verzenio may be reduced or stopped by the patient’s doctor depending on how the individual patient tolerates the treatment.1Patients should take their medication as prescribed by their doctor. Patients should talk to their doctor if they have any questions, or if they have questions regarding their Verzenio regimen.
For more information, read the full prescribing information of Verzenio.
Verzenio prescribing information. Eli Lilly and Company. Available at http://uspl.lilly.com/verzenio/verzenio.html#pi. Accessed 7/13/18.
CDK4/6 inhibitors: where they are now and where they are headed in the future. ASCO Post. Available at http://www.ascopost.com/issues/may-10-2017-supplement-cdk46-inhibitors/cdk46-inhibitors-where-they-are-now-and-where-they-are-headed-in-the-future/. Accessed 7/12/18.
Verzenio product website. Eli Lilly and Company. Available at https://www.verzenio.com/. Accessed 7/13/18.